Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Intensive glucose lowering has previously been shown to increase mortality among persons with advanced type 2 diabetes and a high risk of cardiovascular disease. This report describes the 5-year outcomes of a mean of 3.7 years of intensive glucose lowering on mortality and key cardiovascular events. METHODS: We randomly assigned participants with type 2 diabetes and cardiovascular disease or additional cardiovascular risk factors to receive intensive therapy (targeting a glycated hemoglobin level below 6.0%) or standard therapy (targeting a level of 7 to 7.9%). After termination of the intensive therapy, due to higher mortality in the intensive-therapy group, the target glycated hemoglobin level was 7 to 7.9% for all participants, who were followed until the planned end of the trial. RESULTS: Before the intensive therapy was terminated, the intensive-therapy group did not differ significantly from the standard-therapy group in the rate of the primary outcome (a composite of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes) (P=0.13) but had more deaths from any cause (primarily cardiovascular) (hazard ratio, 1.21; 95% confidence interval [CI], 1.02 to 1.44) and fewer nonfatal myocardial infarctions (hazard ratio, 0.79; 95% CI, 0.66 to 0.95). These trends persisted during the entire follow-up period (hazard ratio for death, 1.19; 95% CI, 1.03 to 1.38; and hazard ratio for nonfatal myocardial infarction, 0.82; 95% CI, 0.70 to 0.96). After the intensive intervention was terminated, the median glycated hemoglobin level in the intensive-therapy group rose from 6.4% to 7.2%, and the use of glucose-lowering medications and rates of severe hypoglycemia and other adverse events were similar in the two groups. CONCLUSIONS: As compared with standard therapy, the use of intensive therapy for 3.7 years to target a glycated hemoglobin level below 6% reduced 5-year nonfatal myocardial infarctions but increased 5-year mortality. Such a strategy cannot be recommended for high-risk patients with advanced type 2 diabetes. (Funded by the National Heart, Lung and Blood Institute; ClinicalTrials.gov number, NCT00000620.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Those levels predict the risk of cardiovascular disease.”
From Endpoints for geroscience clinical trials: health outcomes, biomarkers, and biologic age (2022) · cites this paper as [14]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Diabetic kidney disease might also play a role in the arrhythmia-associated mechanism of sudden death in this setting.655”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [655]
Experimental — accuracy not yet measuredIn the citing paper
“However, the belief that HbA1c was a surrogate marker was contradicted by findings from the ACCORD trial that diabetics randomly assigned to intensive treatment that reduced HbA1c levels in fact increased the risk of CVD events [14].”
From Endpoints for geroscience clinical trials: health outcomes, biomarkers, and biologic age (2022) · cites this paper as [14]
In the citing paper
“For example, intensive hypoglycemic treatments, such as oral hypoglycemics and insulin, substantially reduce fasting glucose and HbA1c levels.”
From Endpoints for geroscience clinical trials: health outcomes, biomarkers, and biologic age (2022) · cites this paper as [14]
In the citing paper
“Similar U-shaped curves were found in a 7-year observational study of persons with T1D and a 22-year observational study of >20,000 persons with T2D.83,84”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [83]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Self-citation10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Effects of intensive blood-pressure control in type 2 diabetes mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001286 · Cited by 3,598
Self-citationEffects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837
Self-citationGlycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults
Selvin, E., Steffes, M. W., Zhu, H., Matsushita, K., Wagenknecht, L., Pankow, J., Coresh, J., & Brancati, F. L. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908359 · Cited by 1,544
Huxley, R., Barzi, F., & Woodward, M. (2006) · BMJ · doi:10.1136/bmj.38678.389583.7c · Cited by 1,534
The J-Curve Phenomenon in Hypertension
Kang, Y.-Y., & Wang, J.-G. (2016) · Pulse · doi:10.1159/000446922 · Cited by 1,530
Gerstein, H. C., Miller, M., & Byington, R. P. (2010) · Cited by 981
Bonds, D. E., Miller, M. E., Bergenstal, R. M., Buse, J. B., Byington, R. P., Cutler, J. A., Dudl, R. J., Ismail-Beigi, F., Kimel, A. R., Hoogwerf, B., et al. (2010) · BMJ · doi:10.1136/bmj.b4909 · Cited by 933
Miller, M. E., Bonds, D. E., Gerstein, H. C., Seaquist, E. R., Bergenstal, R. M., Calles-Escandon, J., Childress, R. D., Craven, T. E., Cuddihy, R. M., Dailey, G., et al. (2010) · BMJ · doi:10.1136/bmj.b5444 · Cited by 429
Cited by
Items 201–300 of 1,000
Stroke paradox with SGLT-2 inhibitors: a play of chance or a viscosity-mediated reality?
Imprialos, K. P., Boutari, C., Stavropoulos, K., Doumas, M. N., & Karagiannis, A. I. (2016) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2016-314704 · Cited by 59
Heller, S. R., Bergenstal, R. M., White, W. B., Kupfer, S., Bakris, G. L., Cushman, W. C., Mehta, C. R., Nissen, S. E., Wilson, C. A., Zannad, F., et al. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12871 · Cited by 58
Patoulias, D., Papadopoulos, C. E., Stavropoulos, K., Zografou, I., Doumas, M. N., & Karagiannis, A. I. (2020) · Journal of Clinical Hypertension · doi:10.1111/jch.13831 · Cited by 70
“63,64 As far as RAAS is concerned, it has been recently documented in clinical studies that SGLT-2 inhibitors induce an acute upregulation of RAAS activity (within the first month of treatment), which normalizes after 6 months of treatment,65 while combination therapy with RAAS blockers upregulates the key alternative…”
BackgroundGao, S., Huang, S., Lin, X., Xu, L., & Yu, M. (2023) · Annals of Medicine · doi:10.1080/07853890.2023.2186479 · Cited by 59
“A neutral or even deleterious effect of intensive glucose-lowering therapy was also confirmed in diabetic patients [40,41].”
BackgroundTanaka, R., Yamashiro, K., Okuma, Y., Shimura, H., Nakamura, S., Ueno, Y., Tanaka, Y., Miyamoto, N., Tomizawa, Y., Nakahara, T., et al. (2015) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.30007 · Cited by 56
Clinical Implications of the ACCORD Trial
Genuth, S., & Ismail-Beigi, F. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1679 · Cited by 56
Tomova, G. S., Nimbal, V. C., & Horwich, T. B. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.02.022 · Cited by 66
Epidemiology of Micro- and Macrovascular Complications of Type 2 Diabetes in Korea
Kim, J. H., Kim, D. J., Jang, H. C., & Choi, S. H. (2011) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2011.35.6.571 · Cited by 63
“org a 22% increase in mortality [30,31].”
Gamboa Moreno, E., Mateo-Abad, M., Ochoa de Retana García, L., Vrotsou, K., del Campo Pena, E., Sánchez Perez, Á., Martínez Carazo, C., Arbonies Ortiz, J. C., Rúa Portu, M. Á., Piñera Elorriaga, K., et al. (2019) · Primary Care Diabetes · doi:10.1016/j.pcd.2018.10.001 · Cited by 51
Impact of diabetes mellitus on mortality rates and outcomes in myocardial infarction
Schmitt, V. H., Hobohm, L., Münzel, T. F., Wenzel, P., Gori, T., & Keller, K. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.11.003 · Cited by 63
Approach to diabetes management in patients with CVD
Lathief, S., & Inzucchi, S. E. (2015) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2015.05.005 · Cited by 58
“2 years [46].”
BackgroundInfluentialA stepwise activation model for the insulin receptor
Yunn, N.-O., Kim, J., Ryu, S. H., & Cho, Y. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01101-1 · Cited by 63
Glucose Control and Vascular Outcomes in Type 2 Diabetes: Is the Picture Clear?
Giorgino, F., Home, P. D., & Tuomilehto, J. (2016) · Diabetes Care · doi:10.2337/dcs15-3023 · Cited by 54
Zhu, L., Hayen, A., & Bell, K. J. L. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01002-x · Cited by 54
“CVD: Cardiovascular disease; T2DM: Type 2 diabetes mellitus; ACCORD: Action to Control Cardiovascular Risk in Diabetes; ACCORDION: Action to Control Cardiovascular Risk in Diabetes Follow-On; TRIG: Triglyceride; HDL: High-density lipoprotein; LDL: Low-density lipoprotein; VLDL: Very low-density lipoprotein; MI: Myocar…”
BackgroundInfluentialO’Fee, K., Deych, E., Ciani, O., & Brown, D. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.5726 · Cited by 59
Endpoints for geroscience clinical trials: health outcomes, biomarkers, and biologic age
Cummings, S. R., & Kritchevsky, S. B. (2022) · GeroScience · doi:10.1007/s11357-022-00671-8 · Cited by 54
Hansen, C. R., Perrild, H., Koefoed, B. G., & Zander, M. (2017) · European Journal of Endocrinology · doi:10.1530/eje-16-0811 · Cited by 53
Cahill, L. E., Jensen, M. K., Chiuve, S. E., Shalom, H., Pai, J. K., Flint, A. J., Mukamal, K. J., Rexrode, K. M., Levy, A. P., & Rimm, E. B. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.07.076 · Cited by 56
“5% among participants with diabetes mellitus have found significant reduction in cardiovascular outcomes in some (1,2) but not all (3,4) studies.”
The association of diabetes and dementia and possible implications for nondiabetic populations
Ravona‐Springer, R., & Beeri, M. S. (2011) · Expert Review of Neurotherapeutics · doi:10.1586/ern.11.152 · Cited by 58
“The need for such a personalized approach is emphasized by the recent surprising results from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study, showing increased risk for morbidity and mortality associated with tight diabetes control in some diabetic populations [28–30].”
BackgroundResultDalan, R., Liew, H., Assam, P. N., Chan, E. S., Siddiqui, F. J., Tan, A. W., Chew, D. E. K., Boehm, B. O., & Leow, M. K. (2016) · Diabetes and Vascular Disease Research · doi:10.1177/1479164115621667 · Cited by 52
Cusi, K. (2020) · Liver International · doi:10.1111/liv.14350 · Cited by 51
Mosenzon, O., Raz, I., Scirica, B. M., Hirshberg, B., Stahre, C. I., Steg, P. G., Davidson, J., Ohman, P., Price, D. L., Frederich, B., et al. (2013) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2413 · Cited by 52
“However, tight glycemic control in protocols studying high risk patients at later stages of the disease for shorter periods did not demonstrate a reduction in CV events or mortality [5,6,8,9].”
BackgroundResultKranenburg, G., van der Graaf, Y., van der Leeuw, J., Nathoe, H. M. W., de Borst, G. J., Kappelle, L. J., Visseren, F. L. J., & Westerink, J. (2015) · Diabetes Care · doi:10.2337/dc15-0493 · Cited by 48
Khunti, K., Caputo, S., Damci, T., Dzida, G. J., Ji, Q., Kaiser, M., Karnieli, E., Liebl, A., Ligthelm, R. J., Nazeri, A., et al. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01665.x · Cited by 51
“The association of increased all-cause mortality and severe hypoglycaemia with intensive glycaemic control in higher risk patients may also contribute to reluctance by physicians to strive for tight glycaemic control [17].”
BackgroundIndividualizing Targets and Tactics for High-Risk Patients With Type 2 Diabetes
Riddle, M. C., & Karl, D. M. (2012) · Diabetes Care · doi:10.2337/dc12-0650 · Cited by 51
Dynamic interactions of n-3 and n-6 fatty acid nutrients
Lands, B., Bibus, D. M., & Stark, K. D. (2017) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2017.01.012 · Cited by 58
Prioritization of care in adults with diabetes and comorbidity
Laiteerapong, N., Huang, E. S., & Chin, M. H. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06316.x · Cited by 50
Association Between Obesity and Microvascular Diseases in Patients With Type 2 Diabetes Mellitus
Gao, S., Zhu, Z., Tai, S., 胡信群, & Xing, Z. (2020) · Frontiers in Endocrinology · doi:10.2139/ssrn.3673199 · Cited by 62
Cardiovascular Implications of Hypoglycemia in Diabetes Mellitus
Connelly, K. A., Yan, A. T.-K., Leiter, L. A., Bhatt, D. L., & Verma, S. (2015) · Circulation · doi:10.1161/circulationaha.115.015946 · Cited by 54
Sturek, M. S. (2011) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00373.2011 · Cited by 51
Hunt, L. M., Kreiner, M., & Brody, H. (2012) · The Annals of Family Medicine · doi:10.1370/afm.1380 · Cited by 38
Nonproliferative Diabetic Retinopathy and Diabetic Macular Edema
Wiley, H. E., & Ferris, F. L. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4557-0737-9.00047-3 · Cited by 63
Chen, D., Wang, S.-H., Mao, C., Tsai, M., Lin, Y., Chou, C., Wen, M., Wang, C., Hsieh, C., Hung, K., et al. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.12.029 · Cited by 49
“Patients were excluded if they met any of the following criteria: (1) newly diagnosed T2DM; (2) age < 40 years; (3) expired during index admission; (4) use of other DPP-4 inhibitors before or after the indexed hospitalization; (5) major adverse cardiovascular events (defined as cardiovascular death, MI or ischemic str…”
BackgroundMethodSchott, G., Martinez, Y. V., de Silva, R. E. E., Guiteras, A. R., Vögele, A., Reeves, D., Kunnamo, I., Marttila-Vaara, M., & Sönnichsen, A. C. (2017) · BMC Geriatrics · doi:10.1186/s12877-017-0571-8 · Cited by 51
“Rigid glycaemic control beyond an HbA1c of 8% achieved by antidiabetic drugs may be associated with a higher risk of hypoglycaemia and undesirable long-term outcome like increased mortality [64].”
BackgroundHyperglycemia and Vascular Metabolic Memory: Truth or Fiction?
Bianchi, C., Miccoli, R., & Prato, S. D. (2013) · Current Diabetes Reports · doi:10.1007/s11892-013-0371-2 · Cited by 48
The cardiovascular safety of incretin-based therapies: a review of the evidence
Petrie, J. R. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-130 · Cited by 45
“Improving glycaemic control has provided only limited success in reducing the macrovascular complications associated with T2D [5,6], and so focus has inexorably shifted towards other CV risk factors (including hypertension, dyslipidaemia, and obesity) that contribute to CV morbidity and mortality.”
BackgroundFuture Directions for Cardiovascular Disease Comparative Effectiveness Research
Hlatky, M. A., Douglas, P. S., Cook, N. L., Wells, B. L., Benjamin, E. J., Dickersin, K., Goff, D. C., Hirsch, A. T., Hylek, E. M., Peterson, E. D., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.12.057 · Cited by 54
Hansen, L. J., Siersma, V., Beck‐Nielsen, H., & Olivarius, N. D. F. (2013) · Diabetologia · doi:10.1007/s00125-013-2893-1 · Cited by 48
“Patients’ absolute risk of developing a cardiovascular outcome was greater than in other diabetes trials [1, 3, 6, 9–11, 33, 34] (Table 3).”
BackgroundResultSalt sensitivity, endogenous ouabain and hypertension
Hamlyn, J. M., & Blaustein, M. P. (2012) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e32835b36ec · Cited by 47
Population-Based Cohort Studies: Still Relevant?
Sorlie, P. D., & Wei, G. S. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.08.020 · Cited by 62
Design of ultra-stable insulin analogues for the developing world
Weiss, M. (2013) · Journal of Health Specialties · doi:10.4103/1658-600x.114683 · Cited by 47
“[18] In long-established Type 2 DM; however, the safety of aggressive glycemic targets is unclear with risks of excess deaths raised by the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study.[19,20] Depending on individual metabolic and clinical features,[21] the United Kingdom Prospective Diabetes Study…”
BackgroundDeintensification of Diabetes Medications among Veterans at the End of Life in VA Nursing Homes
Niznik, J. D., Hunnicutt, J. N., Zhao, X., Mor, M. K., Sileanu, F. E., Aspinall, S. L., Springer, S. P., Ersek, M. T., Gellad, W. F., Schleiden, L. J., et al. (2020) · Journal of the American Geriatrics Society · doi:10.1111/jgs.16360 · Cited by 48
Gao, S., Liu, Q., Chen, H., Yu, M., & Li, H. (2021) · BMC Cardiovascular Disorders · doi:10.1186/s12872-021-01962-2 · Cited by 47
The legacy effect in diabetes: are there long-term benefits?
Folz, R., & Laiteerapong, N. (2021) · Diabetologia · doi:10.1007/s00125-021-05539-8 · Cited by 46
Inhibition of Sodium Glucose Cotransporters Improves Cardiac Performance
García‐Ropero, Á., Vargas-Delgado, A. P., Santos‐Gallego, C. G., & Badimón, J. J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133289 · Cited by 49
“Moreover, SGLT2 inhibitors seem to polarize macrophages from a proinflammatory M1 phenotype towards an anti-inflammatory M2 phenotype [60], which would also cause less cardiac damage.”
BackgroundVinci, M. C., Costantino, S., Damiano, G., Rurali, E., Rinaldi, R., Vigorelli, V., Sforza, A., Carulli, E., Pirola, S., Mastroiacovo, G., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02195-1 · Cited by 47
“Hyperglycemia is known to exacerbate CVD, however intensive glucose lowering approaches, a cornerstone of DM treatment, were not associated with a commensurate reduction of CV risk [29–32].”
BackgroundTate, M., Deo, M., Cao, A. H., Hood, S. G., Huynh, K., Kiriazis, H., Du, X., Julius, T. L., Figtree, G. A., Dusting, G. J., et al. (2017) · Diabetes and Vascular Disease Research · doi:10.1177/1479164117710390 · Cited by 50
Xing, Z., Tang, L., Chen, J., Pei, J., Chen, P., Fang, Z., Zhou, S., & Hu, X. (2019) · Canadian Medical Association Journal · doi:10.1503/cmaj.190124 · Cited by 48
Mannucci, E., Gallo, M., Giaccari, A., Candido, R., Pintaudi, B., Targher, G., Monami, M., & Diabetes, T. S. J. P. F. I. G. O. T. O. T. 2. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14888 · Cited by 43
Sardar, P., Udell, J. A., Chatterjee, S., Bansilal, S., Mukherjee, D., & Farkouh, M. E. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.114.001577 · Cited by 48
Alexopoulos, A.-S., Yancy, W. S., Edelman, D., Coffman, C. J., Jeffreys, A. S., Maciejewski, M. L., Voils, C. I., Sagalla, N., Barton Bradley, A., Dar, M., et al. (2021) · Chronic Illness · doi:10.1177/1742395319884096 · Cited by 44
“12,13 This finding highlights the deleterious effects of intensifying therapy in some patients, as well as the need for effective alternatives to medication escalation for improving outcomes in diabetes.”
BackgroundMonami, M., Candido, R., Pintaudi, B., Targher, G., & Mannucci, E. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.05.010 · Cited by 49
Diabetes and Clinical and Subclinical CVD
Bertoni, A. G., Kramer, H., Watson, K., & Post, W. S. (2016) · Global Heart · doi:10.1016/j.gheart.2016.07.005 · Cited by 45
Gorenek, B., Boriani, G., Dan, G.-A., Fauchier, L., Fenelon, G., Huang, H., Kudaiberdieva, G., Lip, G. Y. H., Mahajan, R., Potpara, T., et al. (2018) · EP Europace · doi:10.1093/europace/euy051 · Cited by 43
Update on Type 2 Diabetes as a Cardiovascular Disease Risk Equivalent
Kuusisto, J., & Laakso, M. (2013) · Current Cardiology Reports · doi:10.1007/s11886-012-0331-5 · Cited by 45
Carew, A. S., Levy, A. P., Ginsberg, H. N., Coca, S. G., Lache, O., Ransom, T. P. P., Byington, R. P., Rimm, E. B., Sapp, J. L., Gardner, M., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.11.051 · Cited by 44
Metabolic Disease Drug Discovery— “Hitting the Target” Is Easier Said Than Done
Moller, D. E. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2011.10.012 · Cited by 47
“Findings related to diabetes pathogenesis obtained using mass spectrometry in >2000 blood samples from the Framingham Offspring cohort illustrate this point (Wang et al., 2011).”
BackgroundCardiovascular Outcomes of Patients in SAVOR-TIMI 53 by Baseline Hemoglobin A1c
Cavender, M. A., Scirica, B. M., Raz, I., Steg, P. G., McGuire, D. K., Leiter, L. A., Hirshberg, B., Davidson, J. A., Cahn, A., Mosenzon, O., et al. (2015) · The American Journal of Medicine · doi:10.1016/j.amjmed.2015.09.022 · Cited by 43
“Prior studies have suggested that some antihyperglycemic drugs and strategies of intensive glycemic control may increase the risk of cardiovascular events or death.(5,17) Thus, it is possible that the degree of glycemic control at the time in which a drug is initiated could modify either the benefit or risk associated…”
BackgroundBousser, M. (2012) · Frontiers of Medicine · doi:10.1007/s11684-012-0178-6 · Cited by 47
Efficacy and safety of dapagliflozin in patients with type 2 diabetes and concomitant heart failure
Kosiborod, M., Gause‐Nilsson, I. A. M., Xu, J. L., Sonesson, C., & JOHNSSON, E. K. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2017.02.001 · Cited by 46
Lim, S. K., Eckel, R. H., & Koh, K. K. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.03.013 · Cited by 48
Patient empowerment and optimal glycemic control
White, R. D. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.677417 · Cited by 41
Zabala, A., Darsalia, V., Holzmann, M. J., Franzén, S., Svensson, A., Eliasson, B., Patrone, C., Nyström, T., & Jonsson, M. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13885 · Cited by 41
Li, J., He, K., Ge, J., Li, C., & Jing, Z. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108656 · Cited by 40
Surrogates under scrutiny: fallible correlations, fatal consequences
Moynihan, R. N. (2011) · BMJ · doi:10.1136/bmj.d5160 · Cited by 42
Lega, I. C., Campitelli, M. A., Austin, P. C., Na, Y., Zahedi, A., Leung, F., Yu, C., Bronskill, S. E., Rochon, P. A., & Lipscombe, L. L. (2021) · Diabetologia · doi:10.1007/s00125-020-05370-7 · Cited by 40
“Previous clinical trials reported an increased risk of severe hypoglycaemia with intensive glycaemic control, and even mortality risk [5, 6, 15, 38].”
BackgroundKuhl, J., Sartipy, U., Eliasson, B., Nyström, T., & Holzmann, M. J. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.09.008 · Cited by 41
“Randomized controlled trials investigating the effect of intensive glucose control on the risk of CVD in patients with T2DM have failed to show that better glycemic control prevents macrovascular complications and death [12,35,36].”
BackgroundKenngott, H. G., Clemens, G., Gondan, M., Senft, J., Diener, M. K., Rudofsky, G., Nawroth, P. P., Büchler, M. W., Fischer, L., & Müller-Stich, B. P. (2013) · Trials · doi:10.1186/1745-6215-14-183 · Cited by 40
“The endocrinologists at the participating centers agreed on the standardized medical treatment taking the results of the ACCORD study into account [43].”
The mechanism by which moderate alcohol consumption influences coronary heart disease
Mathews, M. J., Liebenberg, L., & Mathews, E. H. (2015) · Nutrition Journal · doi:10.1186/s12937-015-0011-6 · Cited by 48
“55 [19,76-83,131-136] 56 [19,84-87] 57 [19,84-87,120,137-140] 58 [19,84-87,120] 59 [110-113] 60 [110-113]”
Coronary artery disease and diabetes mellitus
Al-Nozha, M. M., Ismail, H. M., & Nozha, O. M. A. (2016) · Journal of Taibah University Medical Sciences · doi:10.1016/j.jtumed.2016.03.005 · Cited by 62
Caverly, T. J., Fagerlin, A., Zikmund-Fisher, B. J., Kirsh, S., Kullgren, J. T., Prenovost, K., & Kerr, E. A. (2015) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2015.5950 · Cited by 39
Cardioprotective anti-hyperglycaemic medications: a review of clinical trials
Ahmed, H. M., Khraishah, H., & Cho, L. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx668 · Cited by 45
Wu, H., Lau, E. S. H., Yang, A., Zhang, X., Fan, B., Ronald, C. W., Kong, A. P. S., Chow, E., So, W., Chan, J. C. N., et al. (2023) · PLoS Medicine · doi:10.1371/journal.pmed.1004173 · Cited by 44
“Previous studies have indicated that intensive management of blood glucose and other metabolic risk factors will reduce mortality if instituted early in the disease continuum but will have little impact on prognosis in those with established complications [24,25].”
BackgroundFor the CNDDM Working Group, Toscano, C. M., Zhuo, X., Imai, K., Duncan, B. B., Polanczyk, C. A., Zhang, P., Engelgau, M. M., & Schmidt, M. I. (2015) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-015-0090-8 · Cited by 45
“Recent studies have documented that highly intensive glycemic control is not beneficial [42] and have failed to document that intensive treatment after screening [43] reduces cardiovascular events and mortality [44].”
BackgroundChanges in body mass index and waist circumference and heart failure in type 2 diabetes mellitus
Zhou, Y., Chai, X., Yang, G., Sun, X., & Xing, Z. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1305839 · Cited by 38
“This trial ’ s design and main study outcomes have been previously published (14, 15).”
Szwergold, B. S., & Miller, C. B. (2013) · Rejuvenation Research · doi:10.1089/rej.2013.1498 · Cited by 42
Insulin Dose and Cardiovascular Mortality in the ACCORD Trial
Siraj, E. S., Rubin, D. J., Riddle, M. C., Miller, M. E., Hsu, F., Ismail‐Beigi, F., Chen, S.-H., Ambrosius, W. T., Thomas, A., Bestermann, W. H., et al. (2015) · Diabetes Care · doi:10.2337/dc15-0598 · Cited by 42
“(ACCORD) trial, both all-cause and CV mortality were higher with intensive glycemic treatment (4,5).”
BackgroundStabilization of high-risk plaques
Takata, K., Imaizumi, S., Zhang, B., Miura, S., & Saku, K. (2016) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt.2015.10.03 · Cited by 43
Lim, D.-M., Park, K.-Y., Hwang, W.-M., Kim, J.-Y., & Kim, B.-J. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.4279 · Cited by 37
“Thus, even if blood sugar levels are well controlled thereafter, the natural course of macrovascular complications cannot be altered (2).”
Chow, L. S., Zmora, R., Ma, S., Seaquist, E. R., & Schreiner, P. J. (2018) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2018-000527 · Cited by 37
“7 years), participants receiving intensive treatment were transitioned to standard treatment due to higher mortality in the intensive treatment group.(29) Deidentified data from the ACCORD study was obtained from Biologic Specimen and Data Repository (BioLINCC) (https:// biolincc.”
KDOQI US Commentary on the 2017 ACC/AHA Hypertension Guideline
Kramer, H., Townsend, R. R., Griffin, K. A., Flynn, J. T., Weiner, D. E., Rocco, M. V., Choi, M. J., Weir, M. R., Chang, T. I., Agarwal, R., et al. (2019) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2019.01.007 · Cited by 38
Xing, Z., Peng, Z., Wang, X., Zhu, Z., Pei, J., Hu, X., & Chai, X. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01007-6 · Cited by 40
Bacquer, D. D., Dallongeville, J., Kotseva, K., Cooney, M. T., Pająk, A., Deckers, J. W., Mayer, O., Vanuzzo, D., Lehto, S., Fras, Z., et al. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.10.051 · Cited by 37
“Despite the strong impact of raised glucose levels on CVD death rates as seen in our cohort of patients, the observed increase in 5-year all-cause mortality following intensive glucose lowering in CVD patients with advanced Type II diabetes as compared with standard therapy in the ACCORD study, raises nevertheless a w…”
ResultConformational Dynamics of Insulin
Hua, Q. X., Jia, W., & Weiss, M. A. (2011) · Frontiers in Endocrinology · doi:10.3389/fendo.2011.00048 · Cited by 41
“ORIGINAL RESEARCH ARTICLE published: 18 October 2011 doi: 10.3389/fendo.2011.00048”
BackgroundInfluentialQT prolongation caused by insulin-induced hypoglycaemia – An interventional study in 119 individuals
Kacheva, S., Karges, B., Göller, K., Marx, N., Mischke, K., & Karges, W. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.11.021 · Cited by 38
Schubert, U., Schmid, J., Lehmann, S., Zhang, X. Y., Morawietz, H., Block, N. L., Kanczkowski, W., Schally, A. V., Bornstein, S. R., & Ludwig, B. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1221505110 · Cited by 36
Sharma, P. K., Agarwal, S., Ellis, S. G., Goel, S. S., Cho, L., Tuzcu, E. M., Lincoff, A. M., & Kapadia, S. R. (2014) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.113.001107 · Cited by 36
Tian, C., Alomar, F. A., Moore, C. J., Shao, C. H., Kutty, S., Singh, J., & Bidasee, K. R. (2013) · Heart Failure Reviews · doi:10.1007/s10741-013-9384-9 · Cited by 37
“The ACCORD trial also reported that intensive glucose control using complex insulin strategies do not reduce mortality rates in patients with chronic/ long-term type 2 diabetes [10, 11].”
New Developments in Diabetes Management: Medications of the 21st Century
Fonseca, V. A. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.01.018 · Cited by 38
Diabetes and Metabolic Drivers of Trained Immunity: New Therapeutic Targets Beyond Glucose
Choudhury, R. P., Edgar, L., Rydén, M., & Fisher, E. A. A. (2021) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.314211 · Cited by 38
Bonke, F. C., Donnachie, E., Schneider, A., & Mehring, M. (2015) · Diabetologia · doi:10.1007/s00125-015-3797-z · Cited by 38
“In summary, the results of the present study are, to a great extent, in line with findings of previous studies and recommendations like ACCORD [37], the ADA/EASD guidelines [38], which advise focusing more on a patient’s overall condition and comorbidities when determining HbA1c target values.”
ResultThe Quality and Outcomes Framework--where next?
Gillam, S., & Steel, N. (2013) · BMJ · doi:10.1136/bmj.f659 · Cited by 39
Kolaczynski, W. M., Hankins, M. C., Ong, S. H., Richter, H., Clemens, A., & Toussi, M. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0177-8 · Cited by 39
“Similar observations regarding the benefit of intensive glucose treatment in microvascular complications were reported in Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) [27] and Action to Control Cardiovascular Risk in Diabetes (ACCORD; ClinicalTrials.g…”
Sheng, L., Yang, G., Chai, X., Zhou, Y., Sun, X., & Xing, Z. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1323571 · Cited by 37
Sturmberg, J. P., & Topolski, S. (2014) · Journal of Evaluation in Clinical Practice · doi:10.1111/jep.12156 · Cited by 37
Participatory Surveillance of Hypoglycemia and Harms in an Online Social Network
Weitzman, E. R., Kelemen, S., Quinn, M., Eggleston, E. M., & Mandl, K. D. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.2512 · Cited by 35
Veerman, K. J., Venegas-Pino, D. E., Shi, Y., Khan, M., Gerstein, H. C., & Werstuck, G. H. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.01.018 · Cited by 44
“Data from clinical trials examining the effects of intensive glucose lowering indicate that the relationship between blood glucose levels and CV risk is complex [9,10].”
BackgroundHolistic approach to prevention and management of type 2 diabetes mellitus in a family setting
Ofori, S., & Unachukwu, C. (2014) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s62320 · Cited by 47
Huang, G. J., Wang, D., Khan, U. I., Zeb, I., Manson, J. E., Miller, V., Hodis, H. N., Budoff, M. J., Merriam, G. R., HARMAN, M. S., et al. (2012) · Cardiovascular Diabetology · doi:10.1186/1475-2840-11-52 · Cited by 36
“gested by the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial results [35].”
MethodThe design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus
Christensen, M., Miossec, P., Larsen, B. D., Werner, U., & Knop, F. K. (2014) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.942638 · Cited by 34
“(ORIGIN, SAVOR, EXAMINE, ADVANCE, ACCORD [6-11]) have failed to decrease cardiovascular event rates.”
BackgroundInfluential
Metadata
- Authors
- The ACCORD Study Group
- Affiliations
- McMaster University (CA)
- Corresponding author
- The ACCORD Study Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-03-03
- Volume
- 364
- Issue
- 9
- Pages
- 818-828
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4083508
- OpenAlex
- W2125468958
- Cited by
- 1,035
- References
- 18
- Citations by year
- 2026: 12 · 2025: 33 · 2024: 27 · 2023: 35 · 2022: 29 · 2021: 61 · 2020: 51 · 2019: 53 · 2018: 81 · 2017: 78 · 2016: 80 · 2015: 91 · 2014: 100 · 2013: 108 · 2012: 120
- FWCI
- 104.55
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (n01hc95183-23-0-0, n01hc95180-24-0-1, n01hc95184-24-0-1, n01hc95181-23-0-1, n01hc95182-23-0-1, n01hc95178-28-0-1, n01hc95179-25-0-0)
- National Heart, Lung, and Blood Institute (N01- HC-95181, N01 HC095184, N01-HC- 95180, N01-HC-95178, N01 HC095182, N01 HC095181, Y01 HC001010, Y1-HC-9035, N01-HC-095183, N01 HC095178, N01-HC-95184, N01HC95179, N01 HC095180, Y01 HC009035, Y1-HC-1010, N01‐HC‐95183, N01-HC-95182, N01 HC095179)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, HbA1c, cardiovascular outcomes, mortality, myocardial infarction, stroke, cardiovascular disease, glycemic targets, hypoglycemia, adverse events, long-term follow-up, EXSCEL trial
- MeSH terms
- Adult, Aged, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Myocardial Infarction, Proportional Hazards Models, Treatment Outcome, Stroke, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.